Literature DB >> 9309982

Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma.

M Humbert1, C J Corrigan, P Kimmitt, S J Till, A B Kay, S R Durham.   

Abstract

Atopic asthma is characterized by chronic inflammation of the bronchial mucosa in which eosinophil- and immunoglobulin E (IgE)-dependent mechanisms are believed to be prominent. Therefore, specific proeosinophilic mediators such as interleukin (IL)-5 and essential cofactors for IgE switching in B-lymphocytes such as IL-4 could play a pivotal role in asthma. However, the exact role that individual inflammatory mediators play in the development of the disease in humans is still unknown. Using semiquantitative reverse transcriptase-polymerase chain reaction amplification in bronchial biopsies from 10 atopic asthmatics, we have tested the hypothesis that IL-4 and IL-5 mRNA expression relative to beta-actin mRNA correlates with validated indicators of disease severity. IL-4 and IL-5 mRNA copies relative to beta-actin mRNA were detected in bronchial biopsies from atopic asthmatics. The numbers of IL-5 mRNA copies relative to beta-actin mRNA correlated with disease severity assessed by the Aas asthma score (r = 0.70, p = 0.01), baseline FEV1 (r = -0.94, p = 0.001), baseline peak expiratory flow rate (r = -0.77, p = 0.01), peak expiratory flow rate variability over 2 wk (r = 0.69, p = 0.028), and the histamine PC20 (r = -0.72, p = 0.018). Conversely, the numbers of IL-4 mRNA copies relative to beta-actin mRNA did not correlate with asthma severity, but they positively correlated with total serum IgE concentrations (r = -0.90, p = 0.001). Our present results support the concept that IL-5 may determine asthma clinical expression and severity, and by inference they support the development of IL-5 targeted therapies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9309982     DOI: 10.1164/ajrccm.156.3.9610033

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  44 in total

Review 1.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

2.  Airway generation-specific differences in the spatial distribution of immune cells and cytokines in allergen-challenged rhesus monkeys.

Authors:  L A Miller; S D Hurst; R L Coffman; N K Tyler; M Y Stovall; D L Chou; L F Putney; L J Gershwin; E S Schelegle; C G Plopper; D M Hyde
Journal:  Clin Exp Allergy       Date:  2005-07       Impact factor: 5.018

Review 3.  Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma.

Authors:  Douglas A Kuperman; Robert P Schleimer
Journal:  Curr Mol Med       Date:  2008-08       Impact factor: 2.222

Review 4.  Chemokines and their receptors in the allergic airway inflammatory process.

Authors:  Juan Raymundo Velazquez; Luis Manuel Teran
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

Review 5.  Cytokine and anti-cytokine therapy in asthma: ready for the clinic?

Authors:  D Desai; C Brightling
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

Review 6.  Importance of cytokines in murine allergic airway disease and human asthma.

Authors:  Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp
Journal:  J Immunol       Date:  2010-02-15       Impact factor: 5.422

7.  Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma.

Authors:  E L van Rensen; R G Stirling; J Scheerens; K Staples; P J Sterk; P J Barnes; K F Chung
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

8.  Effects of low-dose-gamma rays on the immune system of different animal models of disease.

Authors:  Noriko Shimura; Shuji Kojima
Journal:  Dose Response       Date:  2014-04-23       Impact factor: 2.658

9.  Relationship between Asthma and Rhinitis: Epidemiologic, Pathophysiologic, and Therapeutic Aspects.

Authors:  Celine Bergeron; Qutayba Hamid
Journal:  Allergy Asthma Clin Immunol       Date:  2005-06-15       Impact factor: 3.406

10.  The Saudi Initiative for Asthma.

Authors:  Mohamed S Al-Moamary; Mohamed S Al-Hajjaj; Majdy M Idrees; Mohamed O Zeitouni; Mohammed O Alanezi; Hamdan H Al-Jahdali; Maha Al Dabbagh
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.